The partnership leverages Genenta's robust and well-tested LVV Plasmid DNA technology, a platform developed from the foundational research of Professor Luigi Naldini, co-founder of Genenta. This ...
MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today ...
Investing.com -- Genenta Science (NASDAQ:GNTA) stock soared 241.8% in premarket trading Friday after announcing a strategic collaboration with ANEMOCYTE focused on off-the-shelf lentiviral vector ...
Once an antibody latches on to a pathogen, broadly neutralizing antibodies inactivate it (as their name implies). This is ...
MILAN - Genenta Science (NASDAQ:GNTA), a clinical-stage biotech company with a market capitalization of $61.84 million, and Anemocyte announced Friday a strategic collaboration focused on ...
Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today ...
Genenta Science shares surged by more than double Friday after the company said it has partnered with Anemocyte to collaborate on its plasmid DNA technology platform. The stock was briefly halted from ...
A scaleable method for the liquid-phase separation of plasmid DNA from RNA. In the course of experiments on the potential of nucleic acid compaction for enhancement of chromatographic adsorption ...
Genenta Science (GNTA) and Anemocyte announced a strategic collaboration with a focus on off-the-shelf lentiviral vector Plasmid DNA technology ...
Asianet Newsable on MSN
GNTA Stock Skyrockets 300% Pre-Market Toward Record Highs: What’s Driving The Super Rally?
Genenta Science shares surged 300% in premarket trading on Friday after announcing an expanded collaboration with ANEMOCYTE.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback